Concepedia

Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?

Michele Marchioni, Daniele Amparore, Laura Marandino, Riccardo Bertolo, Selçuk Erdem, Alexandre Ingels, Stijn Muselaers, Önder Kara, Nicola Pavan, Eduard Roussel,

European Urology Open Science · 2022 · 13 citations · 12 references

DOIFull text

Open access

Concepts

Abstract

Contains fulltext : 287565.pdf (Publisher’s version ) (Open Access)

References

12

Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma

Bradley C. Leibovich, Michael L. Blute, John C. Cheville et al. · Cancer · 2003 · 831 citations

, , +17

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · New England Journal of Medicine · 2021 · 746 citations · Full text

, , +13

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

, , +16

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

Sumanta K. Pal, Robert G. Uzzo, José A. Karam et al. · The Lancet · 2022 · 230 citations · Full text

, , +14

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

Thomas Powles, Laurence Albigès, Axel Bex et al. · Annals of Oncology · 2021 · 200 citations · Full text

, , +16